Active ingredientLonafarnibCat. No. P-L088-001CAS 193275-84-2Family · Pharmaceutical analytical standards
Lonafarnib
A farnesyltransferase inhibitor first developed as a potential cancer drug and approved in the United States in November 2020 as the first treatment for Hutchinson-Gilford progeria and some progeroid laminopathies. This family brings together the active ingredient, labelled standards and other impurities.
Did you know?It blocks the attachment of a farnesyl group to progerin, the faulty protein thought to cause progeria. The first-ever clinical trial in this rare disease began in 2007.
Go to the active ingredient →Active ingredientLonafarnibCat. No. P-L088-001CAS 193275-84-2
Isotopically labelledLonafarnib Impurity 1-d7Cat. No. P-L088-002
Isotopically labelledLonafarnib-d9Cat. No. P-L088-003
Isotopically labelledrac-Lonafarnib-d4Cat. No. P-L088-004
ImpurityLonafarnib Impurity 1Cat. No. P-L088-005CAS 817202-01-0No product matches your search.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.